Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
The primary difference between them is their approved indications and the dosage strengths available
The FDA resolved the semaglutide and tirzepatide shortages in 2025, ending the broad shortage-based pathway that powered large-scale compounding, and in April 2026 proposed excluding these drugs from the 503B bulks list, with a comment period through June 29, 2026
Notably, probiotics have shown considerable promise in reducing the incidence of certain cancers, especially colorectal and bladder cancer (296, 297)
Gupta et al., 2012
The price drop comes at a moment when demand is rising and cost remains one of the biggest barriers for patients
According to KFF, both GLP-1 prescriptions and gross spending (Medicaid spending before drug rebates are applied) on GLP-1s have increased rapidly within state Medicaid programs in the past few years
US$ 25.29
US$ 25.60
US$ 25.84
US$ 20.48
US$ 23.33
US$ 21.83
